Cara Therapeutics, Inc. [NASDAQ:CARA]: Analyst Rating and Earnings
Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. For Cara Therapeutics, Inc. [CARA], the latest consensus recommendation available followed its financial results for the fiscal quarter ending in December. On average, stock market experts give CARA an Buy rating. This is compared to its latest closing price of $15.77.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Cara Therapeutics, Inc. [CARA] is sitting at 1.50. This is compared to 1 month ago, when its average rating was 1.50.
Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Thu 21 Mar (In 66 Days).
Fundamental Analysis of Cara Therapeutics, Inc. [CARA]
Now let’s turn to look at profitability: with a current Operating Margin for Cara Therapeutics, Inc. [CARA] sitting at -6529.64.
This company’s Return on Total Capital is -86.52, and its Return on Invested Capital has reached -37.70%. Its Return on Equity is -84.54, and its Return on Assets is -72.28. These metrics suggest that this Cara Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -8.58. The Enterprise Value to Sales for this firm is now 63.79. Cara Therapeutics, Inc. [CARA] has a Price to Book Ratio of 4.61.
Shifting the focus to workforce efficiency, Cara Therapeutics, Inc. [CARA] earns $24,622 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 1.02 and its Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 11.18 and its Current Ratio is 11.18. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Cara Therapeutics, Inc. [CARA] has 39.30M shares outstanding, amounting to a total market cap of $622.12M. Its stock price has been found in the range of 11.46 to 24.30. At its current price, it has moved by -34.86% from its 52-week high, and it has moved 38.13% from its 52-week low.
This stock’s Beta value is currently 3.02, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 54.26. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Cara Therapeutics, Inc. [CARA] a Reliable Buy?
Shares of Cara Therapeutics, Inc. [CARA], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.